促性腺激素释放激素拮抗剂方案与长方案激动剂方案在体外受精中的比较:一项考虑患者类型的系统评价与荟萃分析
该系统评价与荟萃分析纳入50项研究,比较拮抗剂方案与长方案激动剂方案在体外受精或卵胞浆内单精子注射中的效果。在一般体外受精人群中,拮抗剂组的持续妊娠率显著较低(RR 0.89,95%CI 0.82-0.96),但卵巢过度刺激综合征发生率也显著较低。在多囊卵巢综合征和卵巢反应不良患者中,两组持续妊娠率无显著差异,拮抗剂组卵巢过度刺激综合征发生率较低。
要点
- 一般体外受精人群中,拮抗剂组持续妊娠率显著低于激动剂组(RR 0.89,95%CI 0.82-0.96)。
- 多囊卵巢综合征和卵巢反应不良患者中,两组持续妊娠率无显著差异。
- 拮抗剂组卵巢过度刺激综合征发生率在一般人群和多囊卵巢综合征患者中均显著较低。
核心结论
- 在一般体外受精人群中,拮抗剂方案与长方案激动剂相比持续妊娠率较低,但卵巢过度刺激综合征发生率也较低。
- 在多囊卵巢综合征和卵巢反应不良患者中,拮抗剂方案似乎不损害持续妊娠率,且与较少的卵巢过度刺激综合征相关。
研究设计与样本
- 系统评价与荟萃分析,检索Cochrane月经紊乱与生育力审查组对照试验注册库、Pubmed和Embase数据库,从建库至2016年6月。
- 纳入50项研究,其中34项报告一般体外受精患者,10项报告多囊卵巢综合征患者,6项报告卵巢反应不良患者。
- 比较促性腺激素释放激素拮抗剂方案与标准长方案促性腺激素释放激素激动剂方案,主要结局为持续妊娠率。
主要发现
- 一般体外受精患者中,拮抗剂组持续妊娠率显著低于激动剂组(RR 0.89,95%CI 0.82-0.96)。
- 多囊卵巢综合征患者中,拮抗剂组与激动剂组持续妊娠率无显著差异(RR 0.97,95%CI 0.84-1.11)。
- 卵巢反应不良患者中,拮抗剂组与激动剂组持续妊娠率无显著差异(RR 0.87,95%CI 0.65-1.17)。
- 拮抗剂组卵巢过度刺激综合征发生率在一般体外受精患者中显著较低(RR 0.63,95%CI 0.50-0.81),在多囊卵巢综合征患者中也显著较低(RR 0.53,95%CI 0.30-0.95)。
- 卵巢反应不良患者中无卵巢过度刺激综合征数据可用。
关键数值与推荐
- 拮抗剂方案联合口服激素程序化避孕药预处理和灵活方案时,持续妊娠率显著低于长方案激动剂(RR 0.74,95%CI 0.59-0.91);无口服激素程序化避孕药预处理时RR为0.84,95%CI 0.71-1.0。
- 固定拮抗剂方案亚组分析显示,无论是否联合口服激素程序化避孕药预处理,与长方案激动剂相比持续妊娠率均无显著差异(RR 0.94,95%CI 0.79-1.12和RR 0.94,95%CI 0.83-1.05)。
- 在一般体外受精人群中,拮抗剂治疗每40例患者可预防1例卵巢过度刺激综合征,但每28例治疗妇女中减少1例持续妊娠。
临床怎么用
- 在一般体外受精人群中,长方案促性腺激素释放激素激动剂标准治疗可能仍是预防过早黄素化的首选方法。
- 在多囊卵巢综合征和卵巢反应不良夫妇中,促性腺激素释放激素拮抗剂似乎不损害持续妊娠率且与较少的卵巢过度刺激综合征相关,因此可考虑作为标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most reviews of IVF ovarian stimulation protocols have insufficiently accounted for various patient populations, such as ovulatory women, women with polycystic ovary syndrome (PCOS) or women with poor ovarian response, and have included studies in which the agonist or antagonist was not the only variable between the compared study arms. OBJECTIVE AND RATIONALE: The aim of the current study was to compare GnRH antagonist protocols versus standard long agonist protocols in couples undergoing IVF or ICSI, while accounting for various patient populations and treatment schedules. SEARCH METHODS: The Cochrane Menstrual Disorders and Subfertility Review Group specialized register of controlled trials and Pubmed and Embase databases were searched from inception until June 2016. Eligible trials were those that compared GnRH antagonist protocols and standard long GnRH agonist protocols in couples undergoing IVF or ICSI. The primary outcome was ongoing pregnancy rate. Secondary outcomes were: live birth rate, clinical pregnancy rate, number of oocytes retrieved and safety with regard to ovarian hyperstimulation syndrome (OHSS). Separate comparisons were performed for the general IVF population, women with PCOS and women with poor ovarian response. Pre-planned subgroup analyses were performed for various antagonist treatment schedules. OUTCOMES: We included 50 studies. Of these, 34 studies reported on general IVF patients, 10 studies reported on PCOS patients and 6 studies reported on poor responders. In general IVF patients, ongoing pregnancy rate was significantly lower in the antagonist group compared with the agonist group (RR 0.89, 95% CI 0.82-0.96). In women with PCOS and in women with poor ovarian response, there was no evidence of a difference in ongoing pregnancy between the antagonist and agonist groups (RR 0.97, 95% CI 0.84-1.11 and RR 0.87, 95% CI 0.65-1.17, respectively). Subgroup analyses for various antagonist treatment schedules compared to the long protocol GnRH agonist showed a significantly lower ongoing pregnancy rate when the oral hormonal programming pill (OHP) pretreatment was combined with a flexible protocol (RR 0.74, 95% CI 0.59-0.91) while without OHP, the RR was 0.84, 95% CI 0.71-1.0. Subgroup analysis for the fixed antagonist schedule demonstrated no evidence of a significant difference with or without OHP (RR 0.94, 95% CI 0.79-1.12 and RR 0.94, 95% CI 0.83-1.05, respectively). Antagonists resulted in significantly lower OHSS rates both in the general IVF patients and in women with PCOS (RR 0.63, 95% CI 0.50-0.81 and RR 0.53, 95% CI 0.30-0.95, respectively). No data on OHSS was available from trials in poor responders. WIDER IMPLICATIONS: In a general IVF population, GnRH antagonists are associated with lower ongoing pregnancy rates when compared to long protocol agonists, but also with lower OHSS rates. Within this population, antagonist treatment prevents one case of OHSS in 40 patients but results in one less ongoing pregnancy out of every 28 women treated. Thus standard use of the long GnRH agonist treatment is perhaps still the approach of choice for prevention of premature luteinization. In couples with PCOS and poor responders, GnRH antagonists do not seem to compromise ongoing pregnancy rates and are associated with less OHSS and therefore could be considered as standard treatment.
引用
- Lambalk CB, Banga FR, Huirne JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017. PMID: 28903472. doi:10.1093/humupd/dmx017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。